Proapoptotic Protein Smac Mediates Apoptosis in Ovarian Cancer Cells When Treated with the Carpachromene
IntroductionWe also investigated the Carpachromene in the cytotoxicity studies against common human ovarian cancer cell line i.e., SW 626, in-vitro.Material and methodsCell viability of Carpachromene was very low against common human ovarian cancer cell line i.e. SW 626 without any cytotoxicity on normal cell line. To compare the biological activities of molecules, the enzymes used are α-glucosidase, acetylcholinesterase, respectively. Finally, calculations were made using the molecular docking method to compare the biological activity of the carpachromene molecule. We then examined whether the release of Smac is necessary for apoptosis in ovarian cancer cells using the SW 626 cell line. We first examined mitochondrial and cytosolic Smac levels after Carpachromene treatment. ResultsFollowing the docking calculations, the properties of the carpachromene molecule were examined by ADME/T analysis in order to be used as a drug in the future. In addition, the anti-oxidant properties of the molecules were examined in both gas and water phase with the HF/6-31g basis set with the Gaussian software program. As shown, exposure of ovarian cancer cells to Carpachromene decreased mitochondrial Smac and increased cytosolic Smac levels in a time-dependent fashion. As depicted in results, a decrease in Smac expression was confirmed by Western blot. Silencing of Smac significantly inhibited Carpachromene-induced caspase-3 cleavage and attenuated apoptosis in these cells Moreover, overexpression of a Smac heptapeptide (Smac-N7) enhanced Carpachromene-induced cell deathConclusionsAccording to the above findings, the Carpachromene may be administrated for the treatment of several types of human ovarian cancer in humans.
